ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most advanced next generation pertussis vaccine, today announced the closing of a $42.8 million Class D round of financing. These funds will enable the company to conduct a Phase 2b Human Challenge study to determine if vaccination with BPZE1 prevents colonization from wild-type Bordetella pertussis infection.

ILiAD Biotechnologies is utilizing its B-Tech vector platform to develop next generation vaccines to eradicate infectious diseases and improve lives. Its lead candidate, BPZE1, which has completed Phase 2 clinical trials, is the most advanced next generation vaccine for the prevention of whooping cough, a serious illness caused by Bordetella pertussis.



Iliad Biotechnologies Announces $42.8M Financing Round To Advance Bpze1 Pertussis Vaccine

Description

Company Information

Related People

Funding Insights

Iliad Biotechnologies Announces $42.8M Financing Round To Advance Bpze1 Pertussis Vaccine

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information